HRP20150848T1 - Morfinski spojevi - Google Patents
Morfinski spojevi Download PDFInfo
- Publication number
- HRP20150848T1 HRP20150848T1 HRP20150848TT HRP20150848T HRP20150848T1 HR P20150848 T1 HRP20150848 T1 HR P20150848T1 HR P20150848T T HRP20150848T T HR P20150848TT HR P20150848 T HRP20150848 T HR P20150848T HR P20150848 T1 HRP20150848 T1 HR P20150848T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- diseases
- pain
- homocysteine
- caused
- Prior art date
Links
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 50
- 201000010099 disease Diseases 0.000 claims 26
- 208000002193 Pain Diseases 0.000 claims 24
- 208000035475 disorder Diseases 0.000 claims 24
- 230000036407 pain Effects 0.000 claims 18
- 206010054196 Affect lability Diseases 0.000 claims 16
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 12
- 208000006289 Rett Syndrome Diseases 0.000 claims 12
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical group C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 208000004296 neuralgia Diseases 0.000 claims 8
- 208000021722 neuropathic pain Diseases 0.000 claims 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 7
- 206010003805 Autism Diseases 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 208000000094 Chronic Pain Diseases 0.000 claims 6
- 206010011224 Cough Diseases 0.000 claims 6
- 206010012335 Dependence Diseases 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 6
- 208000007101 Muscle Cramp Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- 208000025966 Neurological disease Diseases 0.000 claims 6
- 206010029350 Neurotoxicity Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 208000005392 Spasm Diseases 0.000 claims 6
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 6
- 208000009205 Tinnitus Diseases 0.000 claims 6
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 6
- 230000006907 apoptotic process Effects 0.000 claims 6
- 208000029028 brain injury Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 6
- 230000006735 deficit Effects 0.000 claims 6
- 230000001037 epileptic effect Effects 0.000 claims 6
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 6
- 210000004717 laryngeal muscle Anatomy 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 229960000485 methotrexate Drugs 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 231100000228 neurotoxicity Toxicity 0.000 claims 6
- 230000007135 neurotoxicity Effects 0.000 claims 6
- 229960001404 quinidine Drugs 0.000 claims 6
- 230000003085 retinopathic effect Effects 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 231100000886 tinnitus Toxicity 0.000 claims 6
- 208000011293 voice disease Diseases 0.000 claims 6
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 claims 4
- 238000004806 packaging method and process Methods 0.000 claims 4
- 229960004482 quinidine sulfate Drugs 0.000 claims 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 3
- 229960002870 gabapentin Drugs 0.000 claims 3
- 229960002085 oxycodone Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 230000000155 isotopic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
Claims (22)
1. Tvar formule I:
[image]
ili njena farmaceutski prihvatljiva sol, pri čemu:
R1 je CD3; i
R2 je CH3,
za uporabu u liječenju subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
2. Tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, pri čemu je bilo koji atom koji nije utvrđen da je deuterij prisutan u svom prirodno zastupljenom izotopnom obliku.
3. Apirogeni sastav koji obuhvaća:
tvar ili njenu farmaceutski prihvatljivu sol iz bilo kojeg od prethodnih patentnih zahtjeva, za uporabu u liječenju subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom;
i prihvatljivi nosač.
4. Sastav iz patentnog zahtjeva 3 formuliran za farmaceutsku primjenu i pri čemu je nosač farmaceutski prihvatljivi nosač.
5. Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 4, za uporabu u liječenju neuropatske boli ili pseudobulbarnog afekta.
6. Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 5, za uporabu u liječenju pseudobulbarnog afekta.
7. Sastav u skladu s bilo kojim od patentnih zahtjeva 3-6, nadalje obuhvaća drugi terapijski agens koristan u liječenju ili sprečavanju bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
8. Sastav iz patentnog zahtjeva 7, pri čemu je drugi terapijski agens odabran između kinidina, kinidin sulfata, oksikodona i gabapentina.
9. Zasebni oblici doziranja:
I. tvari, njena farmaceutski prihvatljiva sol ili sastav prema bilo kojem od patentnih zahtjeva 1-4; i
II. drugi terapijski agens koristan u liječenju ili sprečavanju bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom,
pri čemu navedena tvar, njena farmaceutski prihvatljiva sol ili sastav i drugi terapijski agens nisu međusobno povezani.
10. Zasebni oblici doziranja u skladu s patentnim zahtjevom 9, pri čemu je navedeni drugi terapijski agens odabran između kinidina, kinidin sulfata, oksikodona i gabapentina.
11. Pakiranje koje obuhvaća zasebne oblike doziranja u skladu s patentnim zahtjevom 9 ili 10.
12. Zasebni oblici doziranja ili pakiranje u skladu s bilo kojim od patentnih zahtjeva 9-11, pri čemu je navedeni drugi terapijski agens za istovremenu primjenu.
13. Zasebni oblici doziranja ili pakiranje u skladu s bilo kojim od patentnih zahtjeva 9-11, pri čemu je navedeni drugi terapijski agens za zasebnu primjenu.
14. Sastav, zasebni oblici doziranja ili pakiranje u skladu s bilo kojim od patentnih zahtjeva 7-13, za uporabu u liječenju subjekta subjekta koji pati od ili je podložan dijabetičkoj neuropatiji, pri čemu je drugi agens kinidin sulfat.
15. Sastav, zasebni oblici doziranja ili pakiranje u skladu s bilo kojim od patentnih zahtjeva 7-14, koji obuhvaćaju 10-60 mg tvari formule I ili njene farmaceutski prihvatljive soli, i 2.5-30 mg kinidina.
16. Uporaba tvari formule I
[image]
ili njene farmaceutski prihvatljive soli, pri čemu:
R1 je CD3; i
R2 je CH3,
za uporabu u proizvodnji lijeka za liječenje subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
17. Uporaba u skladu s patentnim zahtjevom 16, pri čemu je bilo koji atom koji nije utvrđen da je deuterij prisutan u svom prirodno zastupljenom izotopnom obliku.
18. Uporaba u skladu s patentnim zahtjevom 16 ili 17, pri čemu je bolest ili stanje neuropatska bol ili pseudobulbarni afekt.
19. Uporaba u skladu s patentnim zahtjevom 18, pri čemu je bolest ili stanje pseudobulbarni afekt.
20. Uporaba iz bilo kojeg od patentnih zahtjeva 16-19, zajedno s drugim terapijskim agensom korisnim u liječenju ili prevenciji bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
21. Uporaba u skladu s patentnim zahtjevom 20, pri čemu je drugi terapijski agens odabran između kinidina, kinidin sulfata, oksikodona i gabapentina.
22. Uporaba u skladu s patentnim zahtjevom 20 ili 21, pri čemu je drugi terapijski agens kinidin, i pri čemu je količina doziranja tvari formule I ili njene farmaceutski prihvatljive soli 10-60 mg, a količina doziranja kinidina je 2.5-30 mg.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91513007P | 2007-05-01 | 2007-05-01 | |
| US91666207P | 2007-05-08 | 2007-05-08 | |
| US97604407P | 2007-09-28 | 2007-09-28 | |
| EP11000764.8A EP2357183B1 (en) | 2007-05-01 | 2008-04-30 | Morphinan compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150848T1 true HRP20150848T1 (hr) | 2015-09-25 |
Family
ID=51894365
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230745TT HRP20230745T3 (hr) | 2007-05-01 | 2008-04-30 | Spojevi morfina |
| HRP20140903AT HRP20140903T1 (hr) | 2007-05-01 | 2014-09-22 | Morfinski spojevi |
| HRP20150809TT HRP20150809T1 (hr) | 2007-05-01 | 2015-07-24 | Spojevi morfinana |
| HRP20150848TT HRP20150848T1 (hr) | 2007-05-01 | 2015-08-10 | Morfinski spojevi |
| HRP20160521TT HRP20160521T8 (hr) | 2007-05-01 | 2016-05-16 | Morfinski spojevi |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230745TT HRP20230745T3 (hr) | 2007-05-01 | 2008-04-30 | Spojevi morfina |
| HRP20140903AT HRP20140903T1 (hr) | 2007-05-01 | 2014-09-22 | Morfinski spojevi |
| HRP20150809TT HRP20150809T1 (hr) | 2007-05-01 | 2015-07-24 | Spojevi morfinana |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160521TT HRP20160521T8 (hr) | 2007-05-01 | 2016-05-16 | Morfinski spojevi |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9314440B2 (hr) |
| EP (5) | EP3093290B1 (hr) |
| BR (1) | BRPI0811478B8 (hr) |
| CA (3) | CA2945581C (hr) |
| CY (1) | CY1117826T1 (hr) |
| DK (4) | DK2357183T3 (hr) |
| ES (5) | ES2523286T3 (hr) |
| FI (1) | FI3825306T3 (hr) |
| HK (5) | HK1178154A1 (hr) |
| HR (5) | HRP20230745T3 (hr) |
| HU (3) | HUE025569T2 (hr) |
| LT (1) | LT3825306T (hr) |
| PL (3) | PL2357183T3 (hr) |
| PT (5) | PT2792662T (hr) |
| SI (2) | SI2792662T1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4183787A1 (en) * | 2007-05-01 | 2023-05-24 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| PT2792662T (pt) | 2007-05-01 | 2016-07-07 | Concert Pharmaceuticals Inc | Compostos de morfinano |
| WO2017020002A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| US20180296647A1 (en) | 2015-10-14 | 2018-10-18 | Kurume University | Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient |
| AU2018210230A1 (en) * | 2017-01-19 | 2019-09-05 | Donald Danforth Plant Science Center | Morphinan N-demethylase isolated from the Methylobacterium Thebainfresser and methods of use thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US38115A (en) | 1863-04-07 | Improvement in turning edges of plates or metal sheets | ||
| GB713146A (en) | 1951-10-18 | 1954-08-04 | Roche Products Ltd | Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof |
| US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
| US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
| JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤 |
| US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| US4898860A (en) | 1985-08-16 | 1990-02-06 | New York University | Anticonvulsant composition and method |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5336980A (en) | 1992-12-10 | 1994-08-09 | Leopold Kostal Gmbh & Co. | Apparatus and method for controlling a windshield wiping system |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| WO1996009044A1 (en) | 1994-09-22 | 1996-03-28 | Richard Alan Smith | Compositions useful for the preparation of medicines for treating a variety of intractable disorders |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| CH690817A5 (de) | 1996-09-03 | 2001-01-31 | Flachsmann Ag Emil | Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes. |
| US6187782B1 (en) | 1997-03-27 | 2001-02-13 | Toray Industries, Inc. | Morphinane derivatives and medicinal use thereof |
| US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| WO1999038499A2 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| WO2001041707A2 (en) | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| US20040087479A1 (en) | 2001-04-30 | 2004-05-06 | Sosnowski Robert E. | Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases |
| US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
| CZ20033211A3 (cs) | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| UA77234C2 (en) | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
| WO2003097608A2 (en) | 2002-05-17 | 2003-11-27 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| DE102004009445A1 (de) | 2004-02-27 | 2005-09-29 | Chemetall Gmbh | Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie |
| AU2005244401B2 (en) | 2004-05-14 | 2009-01-22 | Green Cross Corp. | Neuroprotective properties of dextrorotatory morphinans |
| AU2005292339A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| US20070191411A1 (en) | 2004-10-07 | 2007-08-16 | Smith Richard A | Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor |
| US7114547B2 (en) | 2005-01-11 | 2006-10-03 | Sullivan Michael R | Casting ring |
| WO2007012651A1 (en) | 2005-07-26 | 2007-02-01 | Nycomed Gmbh | Isotopically substituted pantoprazole |
| CN101273024A (zh) | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
| CA2624179A1 (en) | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CN101528269A (zh) | 2006-08-16 | 2009-09-09 | 奥斯拜客斯制药有限公司 | 阿片样物质止痛剂的制备和应用 |
| WO2008030382A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| WO2008097924A2 (en) | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| WO2008137474A1 (en) | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| PT2792662T (pt) | 2007-05-01 | 2016-07-07 | Concert Pharmaceuticals Inc | Compostos de morfinano |
| PL3248978T3 (pl) | 2008-09-19 | 2019-12-31 | Concert Pharmaceuticals Inc. | Zdeuterowane związki morfinanu |
| EP3090760A1 (en) | 2008-10-30 | 2016-11-09 | Concert Pharmaceuticals, Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| JP6525419B2 (ja) | 2015-01-15 | 2019-06-05 | 株式会社半導体エネルギー研究所 | 二次電池 |
-
2008
- 2008-04-30 PT PT141731901T patent/PT2792662T/pt unknown
- 2008-04-30 DK DK11000764.8T patent/DK2357183T3/en active
- 2008-04-30 EP EP16163718.6A patent/EP3093290B1/en active Active
- 2008-04-30 EP EP17206213.5A patent/EP3357923B1/en active Active
- 2008-04-30 PL PL11000764T patent/PL2357183T3/pl unknown
- 2008-04-30 PT PT202006334T patent/PT3825306T/pt unknown
- 2008-04-30 PT PT110007648T patent/PT2357183E/pt unknown
- 2008-04-30 EP EP14173190.1A patent/EP2792662B1/en active Active
- 2008-04-30 ES ES12176476.5T patent/ES2523286T3/es active Active
- 2008-04-30 CA CA2945581A patent/CA2945581C/en active Active
- 2008-04-30 SI SI200831620A patent/SI2792662T1/sl unknown
- 2008-04-30 ES ES12176544.0T patent/ES2536984T3/es active Active
- 2008-04-30 HU HUE11000764A patent/HUE025569T2/en unknown
- 2008-04-30 EP EP11000764.8A patent/EP2357183B1/en active Active
- 2008-04-30 DK DK12176544.0T patent/DK2522668T3/en active
- 2008-04-30 SI SI200832212T patent/SI3825306T1/sl unknown
- 2008-04-30 ES ES14173190.1T patent/ES2577477T3/es active Active
- 2008-04-30 DK DK20200633.4T patent/DK3825306T3/da active
- 2008-04-30 HR HRP20230745TT patent/HRP20230745T3/hr unknown
- 2008-04-30 ES ES20200633T patent/ES2951028T3/es active Active
- 2008-04-30 DK DK14173190.1T patent/DK2792662T3/da active
- 2008-04-30 HU HUE14173190A patent/HUE029782T2/en unknown
- 2008-04-30 CA CA3208128A patent/CA3208128A1/en active Pending
- 2008-04-30 EP EP20200633.4A patent/EP3825306B8/en active Active
- 2008-04-30 HU HUE20200633A patent/HUE063526T2/hu unknown
- 2008-04-30 BR BRPI0811478A patent/BRPI0811478B8/pt active IP Right Grant
- 2008-04-30 FI FIEP20200633.4T patent/FI3825306T3/fi active
- 2008-04-30 ES ES11000764.8T patent/ES2545617T3/es active Active
- 2008-04-30 PL PL14173190.1T patent/PL2792662T3/pl unknown
- 2008-04-30 PL PL20200633.4T patent/PL3825306T3/pl unknown
- 2008-04-30 PT PT121765440T patent/PT2522668E/pt unknown
- 2008-04-30 LT LTEP20200633.4T patent/LT3825306T/lt unknown
- 2008-04-30 PT PT121764765T patent/PT2522667E/pt unknown
- 2008-04-30 CA CA3056205A patent/CA3056205C/en active Active
-
2010
- 2010-07-22 HK HK13105154.6A patent/HK1178154A1/xx unknown
- 2010-07-22 HK HK15101294.4A patent/HK1201058A1/zh unknown
- 2010-07-22 HK HK11109620.6A patent/HK1155442A1/xx unknown
- 2010-07-22 HK HK13105601.5A patent/HK1178889A1/xx unknown
-
2014
- 2014-07-17 US US14/334,227 patent/US9314440B2/en active Active
- 2014-09-22 HR HRP20140903AT patent/HRP20140903T1/hr unknown
-
2015
- 2015-07-24 HR HRP20150809TT patent/HRP20150809T1/hr unknown
- 2015-08-10 HR HRP20150848TT patent/HRP20150848T1/hr unknown
-
2016
- 2016-03-11 US US15/068,404 patent/US9868976B2/en active Active
- 2016-05-16 HR HRP20160521TT patent/HRP20160521T8/hr unknown
- 2016-07-05 CY CY20161100624T patent/CY1117826T1/el unknown
-
2017
- 2017-05-02 HK HK19101064.8A patent/HK1259133A1/zh unknown
- 2017-12-12 US US15/839,387 patent/US20180327809A1/en not_active Abandoned
-
2020
- 2020-12-14 US US17/120,880 patent/US11473123B2/en active Active
-
2022
- 2022-09-12 US US17/942,555 patent/US20240093265A1/en active Pending
-
2023
- 2023-04-25 US US18/306,710 patent/US20240117407A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150848T1 (hr) | Morfinski spojevi | |
| JP2021105032A5 (hr) | ||
| JP2013526544A5 (hr) | ||
| RU2014121065A (ru) | Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение | |
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2010535801A5 (hr) | ||
| JP2023181322A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2007533691A (ja) | 下肢静止不能症候群および嗜癖障害の処置に有用なα−アミノアミド誘導体 | |
| SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
| US20100204205A1 (en) | Tolerability of mirtazapine and a second active agent by using them in combination | |
| WO2010150261A1 (en) | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition | |
| US20220096444A1 (en) | Prophylactic or therapeutic agent for delirium | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| IT201800004108A1 (it) | Composizione a base naturale per l’uso nel trattamento dello stress cronico caratterizzato da disturbi dell’umore e/o ansia | |
| ES2822562T3 (es) | Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos | |
| JP2016507500A5 (hr) | ||
| WO2021259962A1 (en) | Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy | |
| WO2008122019A1 (en) | Improving the tolerability of both mirtazapine and reboxetine by using them in combination | |
| JP2016505050A5 (hr) | ||
| JP4746714B2 (ja) | 線維筋痛症治療用医薬組成物 | |
| US20090048233A1 (en) | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination | |
| JP6943994B2 (ja) | 神経精神系障害の治療のための組成物および方法 | |
| Gil-Ad et al. | A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia |